Clinical Trials Browser

Phase 2 × Endometrial Neoplasms × sacituzumab govitecan × Clear all

NCT04251416 2026-02-17

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Phase 2 Active not recruiting

Endometrial Neoplasms